Magnitude and duration of the effect of sepsis on survival

JAMA

Volumn 277, Issue 13, 1997, Pages 1058-1063

  Quartin, Andrew A ^a,c   Schein, Roland M H ^a   Kett, Daniel H ^a   Peduzzi, Peter N ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b Dept Vet Aff Coop Studs P ^*  (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFESPAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; SEPSIS; STEROID THERAPY; SURVIVAL;

EID: 0031003777     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.13.1058     Document Type: Article

References (38)

1. Office of Planning and Extramural Programs and Hospital Care Statistics, Division of Health Care Statistics, National Center for Health Statistics. Increase in national hospital discharge survey rates for septicemia-United States, 1979-1987. MMWR Morb Mortal Wkly Rep. 1990;39:31-34.
2. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) study. JAMA. 1995;274:639-644.
3. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA. 1995;274: 968-974.
4. Kochanek KD, Hudson BL, Division of Vital Statistics. Advance report of final mortality statistics, 1992. Mthly Vital Stat Rep. 1995;43.
5. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose gluco-corticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987; 317:659-665.
6. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
7. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double blind, placebo-controlled trial. N Engl J Med. 1991;324:429-436.
8. Greenman RL, Schein RM, Martin MA, et al, for the XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266:1097-1102.
9. Fisher CJ Jr, Dhainaut JF, Opal SM, et al, for the Phase III rhIL-1ra Sepsis Syndrome Study Group. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA. 1994;271:1836-1843. Correction: JAMA. 1994;272:1170.
10. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA. 1995;273:117-123.
11. McCabe WR, Jackson GG. Gram-negative bacteremia, I: etiology and ecology. Arch Intern Med. 1962;110:847-855.
12. Hodgin UG, Sanford JP. Gram negative rod bacteremia: an analysis of 100 patients. Am J Med. 1965;39:952-960.
13. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia, IV: re-evaluation of clinical features and treatment in 612 patients. Am J Med. 1980;68:344-355.
14. Finland M, Jones WF, Barnes MW. Occurrence of serious bacterial infections since introduction of antibacterial agents. JAMA. 1959;170:2188.
15. Bryant RE, Hood AF, Hood CE, Koenig MG. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971;127:120-128.
16. Pittet D, Thievent B, Wenzel RP, Li N, Gurman G, Suter PM. Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med. 1993;19:265-272.
17. Knaus WA, Harrell FE, Fisher CJ Jr, et al. The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA. 1993;270:1233-1241.
18. Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia or fungemia. JAMA. 1995;274: 807-812.
19. Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA. 1995;274:338-345.
20. Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu T. Long-term survival after intensive care unit admission with sepsis. Crit Care Med. 1995;23:1040-1047.
21. Bates DW, Pruess KE, Lee TH. How bad are bacteremia and sepsis? outcomes in a cohort with suspected bacteremia. Arch Intern Med. 1995;155: 593-598.
22. Peduzzi P, Shatney C, Sheagren J, Sprung C. Predictors of bacteremia and gram-negative bacteremia in patients with sepsis: the Veterans Affairs Systemic Sepsis Cooperative Study Group. Arch Intern Med. 1992;152:529-535.
23. The ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101:1644-1655.
24. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
25. Knaus WA, Harrell FE, Lynn J, et al. The SUPPORT prognostic model: objective estimates of survival for seriously ill hospitalized adults. Ann Intern Med. 1995;122:191-203.
26. Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis: economic assessment of a new therapeutic agent. JAMA. 1991;266: 3466-3471.
27. Rutenberg AM, Sonnenblick E, Koven I, Schweinberg F, Fine J. Comparative response of normal and cirrhotic rats to intravenously injected bacteria. Proc Soc Exp Biol Med. 1959;101:279-281.
28. Aloy DA, Espejo AE, Mauri PM, Garcia RE, Simo SM, Bella CF. Bacteremia in the patient with liver cirrhosis: prospective study of 61 episodes. Enferm Infecc Microbiol Clin. 1990;8:540-543.
29. Green J, Better OS. Systemic hypotension and renal failure in obstructive jaundice: mechanistic and therapeutic aspects. J Am Soc Nephrol. 1995; 5:1853-1871.
30. Moss M, Bucher B, Moore FA, Moore EE, Parsons PE. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. JAMA. 1996;275:50-54.
31. Elliot CG. Pulmonary sequelae in survivors of the adult respiratory distress syndrome. Clin Chest Med. 1990;11:789-800.
32. Ghio AJ, Elliot CG, Crapo RO, Berlin SL, Jensen RL. Impairment after adult respiratory distress syndrome: an evaluation based on American Thoracic Society recommendations. Am Rev Respir Dis. 1989;139:1158-1162.
33. Elliot CG, Rasmusson BY, Crapo RO, Morris AH, Jensen RL. Prediction of pulmonary function abnormalities after adult respiratory distress syndrome (ARDS). Am Rev Respir Dis. 1988;135:634-638.
34. Peters JI, Bell RC, Prihoda TJ, Harris G, Andrews C, Johanson WG. Clinical determinants of abnormalities in pulmonary function in survivors of the adult respiratory distress syndrome. Am Rev Respir Dis. 1989;139:1163-1168.
35. Hall JW, Johnson WJ, Maher FT, Hunt JC. Immediate and long-term prognosis in acute renal failure. Ann Intern Med. 1970;73:515-521.
36. Lewers DT, Mathew TH, Maher JF, Schreiner GE. Long-term follow-up of renal function and histology after acute tubular necrosis. Ann Intern Med. 1970;73:523-529.
37. Chertow GM, Christiansen CL, Cleary PD, Munro C, Lazarus JM. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med. 1995;155:1505-1511.
38. Leijten FSS, Harinck-de Weerd JE, Poortvliet DCJ, de Weerd AW. The role of polyneuropathy in motor convalescence after prolonged mechanical ventilation. JAMA. 1995;274:1221-1225.